NATICK, MA, UNITED STATES - Oct 26, 2017 -
October 26, 2017 12:15 PM EST
Pillar Biosciences to Collaborate with Illumina on Next-Generation Sequencing Based In Vitro Diagnostics Development
Illumina and Pillar Biosciences, Inc. today announced an agreement to develop next-generation sequencing (NGS) based
in vitro
diagnostic (IVD) tests. Under terms of the agreement, Pillar Biosciences will lead the development of a series of diagnostic tests that will be run on the Illumina MiSeqDx® instrument.
Pillar Biosciences has developed Stem Loop Inhibition Mediated Amplification (SLIMamp®), an innovative technology to maximize the efficiency and performance of targeted NGS panels for the clinical user.
Gang Song, Ph.D., CEO of Pillar Biosciences, stated: The combination of two state-of the-art NGS technologies, SLIMamp and MiSeqDx, is enabling affordable precision medicine. SLIMamp library preparation combined with MiSeqDx makes NGS accessible to clinical laboratories.
The SLIMamp technology is optimized for highly multiplexed reactions from a single tube with as little as 2.5 ng of DNA supporting sequencing from FFPE and biofluids. Specifically designed to enable automation, it offers a unique technology that can leverage the power of the MiSeqDx to provide superior uniformity and specificity. SLIMamp based NGS panels provide highly sensitive variant detection in regions of interest including GC rich regions and low quality samples. Pillar intends to submit multiple NGS assays to the FDA starting in 2018.
About Pillar Biosciences
Pillar Biosciences is a clinical cancer diagnostics company. We create precision NGS panels and software solutions to make clinical NGS fast and cost-effective. Our SLIMamp based products are intended to deliver the most value to high-throughput reference labs and clinical oncology labs.
To learn more, visit
https://pillar-biosciences.com/
.
Pillar Biosciences: For questions and media inquiries please contact us at
marketing@pillar-biosciences.com
.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit
www.illumina.com
and follow @illumina.